GlassScriptPhysician profile
Stephen J Bigelsen
NPI 1780611574
$4,943.90
in general payments reported to CMS, 2019-2025
19 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $3,136 · 2021: $215 · 2022: $295 · 2023: $222 · 2024: $155 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499 · Education: $88.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.97 |
| Education | $88.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $2,425.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $564.34 | 2019-2024 | Tezspire |
| Eyevance Pharmaceuticals LLC | $500.00 | 2020 | |
| Glaxosmithkline, LLC. | $408.52 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $359.08 | 2019-2025 | |
| Amgen INC. | $134.51 | 2021-2025 | Tezspire, Enbrel |
| Janssen Biotech, INC. | $85.84 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $76.16 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $70.60 | 2025 | Neffy |
| Ucb, INC. | $66.09 | 2021-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Genzyme Corporation | $50.80 | 2019-2025 | |
| Kaleo, INC. | $41.20 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $27.52 | 2019 | |
| Genentech USA, INC. | $25.74 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.53 | 2019 | |
| Aimmune Therapeutics, INC. | $13.96 | 2022 | |
| Covis Pharma Gmbh | $13.52 | 2019 | |
| Hikma Pharmaceuticals USA | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bigelsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.